Passage Bio

Today, Passage Bio announced a merger agreement with @RemixThera, a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease. Learn more about the proposed transaction:bit.ly/4uTCLce

Find us at the @AFTDHope Education Conference to meet our team, learn more about FTD, and discover how we’re advancing research to support the community: bit.ly/3NC20QX

#FTD
#FrontotemporalDementia
#AFTDConference
#MedEd

Today, Passage Bio shared updated interim data from the ongoing Phase 1/2 upliFT-D trial of PBFT02 in frontotemporal dementia caused by GRN mutations, along with regulatory and corporate updates. Read more here: loom.ly/bhGLs-4

#FTD
#GeneticMedicine
#ClinicalTrials

We announced our Q4 and full year 2025 financial results and highlighted meaningful progress as we advance our upliFT-D clinical trial in frontotemporal dementia (FTD) and our differentiated preclinical Huntington’s disease program: loom.ly/bAzuoJk

Passage Bio will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference and TD Cowen 46th Annual Health Care Conference, where we will present updates on our progress advancing genetic medicines for neurodegenerative diseases: bit.ly/4rsc3qs